JDRF and Becton, Dickinson and Company (BD) are accelerating the development of new products that combine BD's insulin infusion and glucose sensing technologies through a new three-year collaboration. This commitment is an extension of ...
MannKind has completed the Phase 3 clinical study of Afrezza (insulin human [rDNA origin]) in patients with type 1 diabetes and expects to release the data in the summer of 2013. Administered using MannKind's next-generation inhaler, the ...
National Institutes of Health's National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),US, has awarded $500,000 small business innovation research (SBIR) grant to Genalyte to develop multiplexed diagnostic assays for the ...
Tags: diabetes, digestive, kidney diseases, health
The FDA has granted orphan drug designation for Andromeda Biotech's DiaPep277 to treat type 1 diabetes (T1D) patients with residual beta cell function. The orphan drug status offers seven years marketing exclusivity from the time of ...
Tags: DiaPep277, type 1 diabetes, T1D, residual beta cell
ViaCyte has received a $10.1m strategic partnership award from the California Institute for Regenerative Medicine (CIRM) to develop VC-01, which is a regenerative medicine, consisting of pancreatic beta cell progenitors in a durable ...
Tags: ViaCyte, Diabetes Therapy Development, CIRM
The FDA has approved Novo Nordisk Levemir (insulin detemir [rDNA origin] injection) for use in children with type 1 diabetes. The basal insulin analog is approved for type 1 diabetes patients from age two through adulthood and adult ...
Tags: FDA, Levemir, treatment for type 1 diabetes